Global Wealth Strategies & Associates Purchases 250 Shares of Boston Scientific Co. (NYSE:BSX)

Global Wealth Strategies & Associates grew its position in shares of Boston Scientific Co. (NYSE:BSX) by 423.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 309 shares of the medical equipment provider’s stock after purchasing an additional 250 shares during the quarter. Global Wealth Strategies & Associates’ holdings in Boston Scientific were worth $28,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Values First Advisors Inc. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at about $28,000. Dunhill Financial LLC boosted its stake in shares of Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 152 shares during the period. Andra AP fonden bought a new position in shares of Boston Scientific in the second quarter worth approximately $29,000. E Fund Management Hong Kong Co. Ltd. purchased a new position in shares of Boston Scientific in the third quarter worth $30,000. Finally, Capital Performance Advisors LLP bought a new stake in Boston Scientific during the 3rd quarter valued at $30,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now directly owns 1,572,096 shares in the company, valued at $133,046,484.48. This represents a 9.38 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now owns 39,398 shares in the company, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 321,174 shares of company stock valued at $27,372,081. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

BSX traded down $0.23 during midday trading on Thursday, reaching $89.09. The company had a trading volume of 1,361,992 shares, compared to its average volume of 5,932,722. The business has a 50-day moving average of $88.77 and a two-hundred day moving average of $83.06. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 1 year low of $57.33 and a 1 year high of $91.93. The company has a market cap of $131.30 billion, a P/E ratio of 73.63, a P/E/G ratio of 2.67 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm’s revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.50 EPS. As a group, equities research analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on BSX. Royal Bank of Canada boosted their price target on Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. Sanford C. Bernstein boosted their target price on Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Wells Fargo & Company raised their price target on Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Finally, Mizuho raised their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.